The fin roundabout: Slit-Robo and S1P signaling coordinate fin morphogenesis.
Journal
EMBO reports
ISSN: 1469-3178
Titre abrégé: EMBO Rep
Pays: England
ID NLM: 100963049
Informations de publication
Date de publication:
03 08 2022
03 08 2022
Historique:
received:
09
06
2022
accepted:
01
07
2022
pubmed:
16
7
2022
medline:
5
8
2022
entrez:
15
7
2022
Statut:
ppublish
Résumé
Development of vertebrate limbs and fins requires that tissue growth is directed outwards, away from the body. How such directed growth is achieved is a fascinating biological problem. For limb/fin formation and outgrowth, signaling between mesenchymal cells and the overlying epithelium is essential. In particular, the epithelium at the distal margin of the growing limb/fin bud, termed the apical ectodermal ridge (AER), promotes directed outgrowth of the underlying mesenchyme, e.g., by providing polarization cues for mesenchymal cell migration. Several classical signaling pathways, such as fibroblast growth factor (Fgf), hedgehog, and Wnt signaling, are involved in the regulation of the cellular events that shape the limb/fin bud (Iovine, 2007). In this issue of EMBO Reports, Carney and colleagues surprisingly find that the Slit-Robo pathway, which is best known for its function in axon guidance, regulates the polarity of developing zebrafish fins (Mahabaleshwar et al, 2007). Intriguingly, they identify an intricate back and forth of signals between the mesenchyme and the AER. Slit ligands derived from mesenchyme act on Robo receptors in the AER to stimulate the production of sphingosine-1-phosphate, which then acts back on the mesenchyme to regulate cell polarity and orientation.
Identifiants
pubmed: 35836403
doi: 10.15252/embr.202255563
pmc: PMC9346477
doi:
Substances chimiques
Zebrafish Proteins
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e55563Informations de copyright
© 2022 The Authors. Published under the terms of the CC BY 4.0 license.
Références
EMBO Rep. 2022 Aug 3;23(8):e55563
pubmed: 35836403
Development. 2016 Sep 1;143(17):3037-44
pubmed: 27578174
Trends Cell Biol. 2012 Jan;22(1):50-60
pubmed: 22001186
Nat Chem Biol. 2007 Oct;3(10):613-8
pubmed: 17876318
Nat Clin Pract Cardiovasc Med. 2007 Feb;4 Suppl 1:S77-82
pubmed: 17230219
PLoS Genet. 2010 Apr 15;6(4):e1000907
pubmed: 20419147
EMBO Rep. 2022 Aug 3;23(8):e54464
pubmed: 35679135
Ann N Y Acad Sci. 2000 Apr;905:301-7
pubmed: 10818470